Clonotypic mass spectrometry with EasyM assay for MRD detection in multiple myeloma

Dr. Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, comments on the feasibility of clonotypic peptides mass spectrometry with EasyM assay for measurable residual disease (MRD) detection in the peripheral blood (PB) of patients with multiple myeloma.